TipRanks
Advertisement
Advertisement

JP:2160 Stock Latest News

GNI Group to Join TOPIX as Global Biopharma Footprint Expands
Company AnnouncementsGNI Group to Join TOPIX as Global Biopharma Footprint Expands
3d ago
GNI Group Wins FDA Approval for First Proprietary Medtech Wound Matrix
PremiumCompany Announcements
GNI Group Wins FDA Approval for First Proprietary Medtech Wound Matrix
1M ago
GNI Group Announces Change in Major Shareholder Following Blackstone-Linked Stake Sale
PremiumCompany Announcements
GNI Group Announces Change in Major Shareholder Following Blackstone-Linked Stake Sale
2M ago
GNI Group Maps Out ‘Second Founding Phase’ in Q2 FY2026 Results
PremiumCompany Announcements
GNI Group Maps Out ‘Second Founding Phase’ in Q2 FY2026 Results
2M ago
GNI Group Lifts 2026 Revenue Outlook After AYUMI Deal, Holds Back Profit Guidance
PremiumCompany Announcements
GNI Group Lifts 2026 Revenue Outlook After AYUMI Deal, Holds Back Profit Guidance
2M ago
GNI Group Narrows Losses in Q2 but Limits FY2026 Guidance to Revenue Amid Drug Investment Uncertainty
PremiumCompany AnnouncementsGNI Group Narrows Losses in Q2 but Limits FY2026 Guidance to Revenue Amid Drug Investment Uncertainty
2M ago
3G6 Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
3G6 Upcoming Earnings Report: What to Expect?
2M ago
GNI Group Makes AYUMI a Wholly Owned Unit and Raises ¥26.8 Billion via Share Issuance
Premium
Company Announcements
GNI Group Makes AYUMI a Wholly Owned Unit and Raises ¥26.8 Billion via Share Issuance
3M ago
GNI Sets July 1 Payment Date for Share Issue Funding AYUMI Acquisition
PremiumCompany Announcements
GNI Sets July 1 Payment Date for Share Issue Funding AYUMI Acquisition
4M ago
GNI Group Secures ¥20 Billion Covenant-Linked Loan for Ayumi Acquisition
PremiumCompany Announcements
GNI Group Secures ¥20 Billion Covenant-Linked Loan for Ayumi Acquisition
4M ago
GNI’s Gyre Therapeutics files Form S-3 tied to Cullgen acquisition
PremiumCompany Announcements
GNI’s Gyre Therapeutics files Form S-3 tied to Cullgen acquisition
4M ago
GNI Group Announces Transformational Acquisition of Ayumi Pharmaceutical Holdings
PremiumCompany Announcements
GNI Group Announces Transformational Acquisition of Ayumi Pharmaceutical Holdings
4M ago
GNI Group to Buy AYUMI Pharmaceutical Holdings and Issue New Shares to Bolster Japan Platform
PremiumCompany AnnouncementsGNI Group to Buy AYUMI Pharmaceutical Holdings and Issue New Shares to Bolster Japan Platform
4M ago
GNI Group to Gain New Largest Shareholder via AYUMI Pharma Deal
Premium
Company Announcements
GNI Group to Gain New Largest Shareholder via AYUMI Pharma Deal
4M ago
GNI Group Outlines Q1 FY2026 Results and Financial Highlights
Premium
Company Announcements
GNI Group Outlines Q1 FY2026 Results and Financial Highlights
5M ago
GNI Group Widens Q1 Loss as Drug Investment and Reorganization Weigh on Earnings
PremiumCompany Announcements
GNI Group Widens Q1 Loss as Drug Investment and Reorganization Weigh on Earnings
5M ago
3G6 Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
3G6 Earnings Report this Week: Is It a Buy, Ahead of Earnings?
5M ago
GNI Group’s F351 Liver Fibrosis Drug Wins NDA Acceptance and Priority Review in China
PremiumCompany Announcements
GNI Group’s F351 Liver Fibrosis Drug Wins NDA Acceptance and Priority Review in China
5M ago
Gyre Ramps Up F351 and Cullgen Investments as Q1 Swings to Loss
PremiumCompany Announcements
Gyre Ramps Up F351 and Cullgen Investments as Q1 Swings to Loss
5M ago
GNI Group Reshapes Top Management as Gyre Advances Cullgen Acquisition
PremiumCompany AnnouncementsGNI Group Reshapes Top Management as Gyre Advances Cullgen Acquisition
5M ago
GNI Group’s Gyre Therapeutics Completes US$300 Million Cullgen Acquisition to Build Integrated U.S.-China Biopharma Platform
Premium
Company Announcements
GNI Group’s Gyre Therapeutics Completes US$300 Million Cullgen Acquisition to Build Integrated U.S.-China Biopharma Platform
5M ago
GNI Group Starts Phase 2/3 Trial of Pirfenidone for Cancer-Related Lung Injury in China
Premium
Company Announcements
GNI Group Starts Phase 2/3 Trial of Pirfenidone for Cancer-Related Lung Injury in China
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >